Affimed N.V. (AFMD): Price and Financial Metrics

Affimed N.V. (AFMD)

Today's Latest Price: $5.13 USD

0.02 (0.39%)

Updated Nov 24 4:00pm

Add AFMD to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 389 in Biotech

See all "A" rated Strong Buy stocks

AFMD Stock Summary

  • Of note is the ratio of Affimed NV's sales and general administrative expense to its total operating expenses; just 9.36% of US stocks have a lower such ratio.
  • For AFMD, its debt to operating expenses ratio is greater than that reported by only 8.73% of US equities we're observing.
  • Revenue growth over the past 12 months for Affimed NV comes in at 171.6%, a number that bests 96.46% of the US stocks we're tracking.
  • If you're looking for stocks that are quantitatively similar to Affimed NV, a group of peers worth examining would be SPRO, CDTX, GRTS, CBIO, and VIR.
  • AFMD's SEC filings can be seen here. And to visit Affimed NV's official web site, go to

AFMD Stock Price Chart Interactive Chart >

Price chart for AFMD

AFMD Price/Volume Stats

Current price $5.13 52-week high $5.24
Prev. close $5.11 52-week low $1.42
Day low $4.96 Volume 1,200,100
Day high $5.24 Avg. volume 1,124,027
50-day MA $3.71 Dividend yield N/A
200-day MA $3.18 Market Cap 391.16M

Affimed N.V. (AFMD) Company Bio

Affimed NV is a clinical-stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies. The company was founded in 2000 and is based in Heidelberg, Germany.

AFMD Latest News Stream

Event/Time News Detail
Loading, please wait...

AFMD Latest Social Stream

Loading social stream, please wait...

View Full AFMD Social Stream

Latest AFMD News From Around the Web

Below are the latest news stories about Affimed NV that investors may wish to consider to help them evaluate AFMD as an investment opportunity.

Affimed N.V. (AFMD) CEO Adi Hoess on Q2 2020 Results - Earnings Call Transcript

Affimed N.V. (AFMD) Q2 2020 Earnings Conference Call August 11, 2020 8:30 a.m. ET Company Participants Alexander Fudukidis - IR Adi Hoess - CEO Andreas Harstrick - Chief Medical Officer Arndt Schottelius - Chief Scientific Officer Angus Smith - CFO Wolfgang Fischer - COO Denise Mueller - Chief Business Officer...

SA Transcripts on Seeking Alpha | August 11, 2020

Introducing Affimed (NASDAQ:AFMD), A Stock That Climbed 76% In The Last Three Years

Affimed N.V. (NASDAQ:AFMD) shareholders might be concerned after seeing the share price drop 22% in the last month...

Yahoo | July 31, 2020

Affimed's Innate Immune Programs Offer A Compelling Value At Current Price Levels

Affimed (AFMD) is another cancer biopharma that fits the mold I like for long-term investments. Their ROCK technology platform holds a lot of promise and has already garnered some measure of clinical validation. On top of that, the partnership with Genentech provides an additional vote of confidence in the technology....

Andy Jones on Seeking Alpha | July 24, 2020

The Daily Biotech Pulse: Ziopharm Starts Blood Cancer Study, Allergan's Botox Gets Label Expansion, 3 IPOs

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 9) Affimed NV (NASDAQ: AFMD ) Altimmune Inc (NASDAQ: ALT ) argenx SE – ADR (NASDAQ: ARGX ) Axonics Modulation Technologies Inc (NASDAQ: AXNX ) Biondvax Pharmaceuticals Ltd – ADR (NASDAQ: BVXV ) Bio-Rad Laboratories, Inc. (NYSE: BIOV ) Cytokinetics, Inc. (NASDAQ: CYTK ) DexCom, Inc. (NASDAQ: DXCMV Dynavax Technologies Corporation (NASDAQ: DVAX ) Eli Lilly And Co (NYSE: LLY ) GENMAB A/S/S ADR (NASDAQ: GMAB ) Horizon Therapeutics PLC (NASDAQ: HZNP ) Immunomedics, Inc. (NASDAQ: IMMU ) Intellia Therapeutics Inc (NASDAQ: NTLA ) ITAMAR MED LTD/S ADR (NASDAQ: ITMR ) Meridian Bioscience, Inc. (NASDAQ: VIVO ) Nantkwest Inc (NASDAQ: NK ) NeoGenomics, Inc. (...

Benzinga | July 10, 2020

Affimed Announces Annual General Meeting of Shareholders

Heidelberg, Germany, July 10, 2020 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight.

Yahoo | July 10, 2020

Read More 'AFMD' Stories Here

AFMD Price Returns

1-mo 55.45%
3-mo 46.57%
6-mo 64.42%
1-year 107.69%
3-year 144.29%
5-year -25.00%
YTD 87.23%
2019 -11.90%
2018 139.23%
2017 -27.78%
2016 -74.72%
2015 14.84%

Continue Researching AFMD

Want to see what other sources are saying about Affimed NV's financials and stock price? Try the links below:

Affimed NV (AFMD) Stock Price | Nasdaq
Affimed NV (AFMD) Stock Quote, History and News - Yahoo Finance
Affimed NV (AFMD) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 1.2266 seconds.